LC–MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma

This publication has 18 references indexed in Scilit:

• Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
  Annals of Oncology, 2012
• The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
  The Oncologist, 2011
• Preformulation stability study of the EGFR inhibitor HKI-272 (Neratinib) and mechanism of degradation
  Drug Development and Industrial Pharmacy, 2011
• The resurgence of covalent drugs
  Nature Reviews Drug Discovery, 2011
• Pharmacokinetics of oral neratinib during co‐administration of ketoconazole in healthy subjects
  British Journal of Clinical Pharmacology, 2011
• Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
  Journal of Clinical Oncology, 2010
• Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations
  The AAPS Journal, 2009
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
  Clinical Cancer Research, 2009
• The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
  Oncogene, 2007
• Review of epidermal growth factor receptor biology
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004